Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. It is primarily used in the treatment of various cancers, including renal cell carcinoma and gastrointestinal stromal tumors. By inhibiting multiple RTKs, sunitinib interferes with tumor growth and angiogenesis.